Ceryvyn Therapeutics Ltd
OPT
Clasificación en acciones
#31853
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Precio por acción
$0.00846342
Última sincronización: 2026-07-27
Capitalización bursátil
$11.27M
Cambio (1 día)
0.00%
Cambio (1 año)
-99.75%
País
AU
Comercio Ceryvyn Therapeutics Ltd (OPT)
Categoría
Healthcare
Ganancias de Ceryvyn Therapeutics Ltd (OPT)
Ganancias en Jun 2025 TTM: $-169.06M
Secondo gli ultimi rapporti finanziari di Ceryvyn Therapeutics Ltd, gli utili attuali della società sono $-169.06M. Nel 2024, la società ha registrato un utile di $-229.65M, una disminución en comparación con agli utili del 2023, che erano di $-220.69M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Ceryvyn Therapeutics Ltd desde 2000 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-169.06M | -1.22% |
| 2025 | $-171.16M | -25.47% |
| 2024 | $-229.65M | 4.06% |
| 2023 | $-220.69M | 61.47% |
| 2022 | $-136.68M | 102.76% |
| 2021 | $-67.41M | 300.56% |
| 2020 | $-16.83M | -32.59% |
| 2019 | $-24.96M | 16.56% |
| 2018 | $-21.42M | 197.14% |
| 2017 | $-7.21M | 19.44% |
| 2016 | $-6.03M | 25.84% |
| 2015 | $-4.80M | -21.15% |
| 2014 | $-6.08M | 11.14% |
| 2013 | $-5.47M | -28.41% |
| 2012 | $-7.64M | -39.60% |
| 2011 | $-12.66M | 157.11% |
| 2010 | $-4.92M | -23.67% |
| 2009 | $-6.45M | 529.14% |
| 2008 | $-1.03M | -111.84% |
| 2007 | $8.66M | -354.34% |
| 2006 | $-3.40M | -126.95% |
| 2005 | $12.63M | 348.18% |
| 2004 | $2.82M | -271.74% |
| 2003 | $-1.64M | -9.95% |
| 2002 | $-1.82M | 332.65% |
| 2001 | $-421.07K | -196.28% |
| 2000 | $437.36K | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -3,220.05% |
US
|
|
| $-3.09B | 1,725.93% |
US
|
|
| $-4.02B | 2,275.54% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,253.79% |
NL
|
